JP2008543871A - チゲサイクリンのための製造プロセス - Google Patents
チゲサイクリンのための製造プロセス Download PDFInfo
- Publication number
- JP2008543871A JP2008543871A JP2008517178A JP2008517178A JP2008543871A JP 2008543871 A JP2008543871 A JP 2008543871A JP 2008517178 A JP2008517178 A JP 2008517178A JP 2008517178 A JP2008517178 A JP 2008517178A JP 2008543871 A JP2008543871 A JP 2008543871A
- Authority
- JP
- Japan
- Prior art keywords
- tigecycline
- solution
- ppm
- water
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004089 tigecycline Drugs 0.000 title claims abstract description 55
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 title claims abstract description 55
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000001301 oxygen Substances 0.000 claims abstract description 38
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000000243 solution Substances 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 21
- 239000007857 degradation product Substances 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 4
- 238000001990 intravenous administration Methods 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 11
- 238000011049 filling Methods 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 4
- 238000004007 reversed phase HPLC Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 abstract description 16
- 238000006731 degradation reaction Methods 0.000 abstract description 16
- 239000008215 water for injection Substances 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000007789 gas Substances 0.000 abstract description 3
- 239000011261 inert gas Substances 0.000 abstract description 2
- 238000001802 infusion Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 239000008364 bulk solution Substances 0.000 description 8
- 238000013329 compounding Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- -1 t-butyl glycyl Chemical group 0.000 description 2
- IQIPCMYBFDOLBO-IRDJJEOVSA-N (4s,4as,5ar,12ar)-9-amino-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(N)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O IQIPCMYBFDOLBO-IRDJJEOVSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- LLJZKKVYXXDWTB-UHFFFAOYSA-N acetic acid;sodium Chemical class [Na].[Na].CC(O)=O LLJZKKVYXXDWTB-UHFFFAOYSA-N 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IVFLPPKNEWVNFG-UHFFFAOYSA-N tetracene-1-carboxamide Chemical class C1=CC=C2C=C(C=C3C(C(=O)N)=CC=CC3=C3)C3=CC2=C1 IVFLPPKNEWVNFG-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
- C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
- C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69117305P | 2005-06-16 | 2005-06-16 | |
| PCT/US2006/023613 WO2006138641A2 (en) | 2005-06-16 | 2006-06-16 | Manufacturing process for tigecycline |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009136753A Division JP2009191083A (ja) | 2005-06-16 | 2009-06-05 | チゲサイクリンのための製造プロセス |
| JP2009254475A Division JP2010024252A (ja) | 2005-06-16 | 2009-11-05 | チゲサイクリンのための製造プロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008543871A true JP2008543871A (ja) | 2008-12-04 |
| JP2008543871A5 JP2008543871A5 (enExample) | 2009-07-23 |
Family
ID=37111782
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517178A Pending JP2008543871A (ja) | 2005-06-16 | 2006-06-16 | チゲサイクリンのための製造プロセス |
| JP2009136753A Withdrawn JP2009191083A (ja) | 2005-06-16 | 2009-06-05 | チゲサイクリンのための製造プロセス |
| JP2009254475A Withdrawn JP2010024252A (ja) | 2005-06-16 | 2009-11-05 | チゲサイクリンのための製造プロセス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009136753A Withdrawn JP2009191083A (ja) | 2005-06-16 | 2009-06-05 | チゲサイクリンのための製造プロセス |
| JP2009254475A Withdrawn JP2010024252A (ja) | 2005-06-16 | 2009-11-05 | チゲサイクリンのための製造プロセス |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7705168B2 (enExample) |
| EP (1) | EP1898884A2 (enExample) |
| JP (3) | JP2008543871A (enExample) |
| KR (1) | KR20080024201A (enExample) |
| CN (1) | CN101198315A (enExample) |
| AR (1) | AR055336A1 (enExample) |
| AU (1) | AU2006261636A1 (enExample) |
| BR (1) | BRPI0612228A2 (enExample) |
| CA (1) | CA2610909A1 (enExample) |
| CR (1) | CR9594A (enExample) |
| EC (1) | ECSP078005A (enExample) |
| GT (1) | GT200600259A (enExample) |
| IL (1) | IL187979A0 (enExample) |
| MX (1) | MX2007015960A (enExample) |
| NO (1) | NO20076264L (enExample) |
| PA (1) | PA8680201A1 (enExample) |
| PE (1) | PE20070072A1 (enExample) |
| RU (1) | RU2007145595A (enExample) |
| SV (1) | SV2007002575A (enExample) |
| TW (1) | TW200716203A (enExample) |
| WO (1) | WO2006138641A2 (enExample) |
| ZA (1) | ZA200710906B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012515753A (ja) * | 2009-01-23 | 2012-07-12 | ホビオネ インテル リミテッド | チゲサイクリンの単離方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649221A1 (en) * | 2006-04-17 | 2007-10-25 | Evgeny Tsiperman | Isolation of tetracycline derivatives |
| DE202007019460U1 (de) * | 2006-04-24 | 2012-10-24 | Teva Pharmaceutical Industries Ltd. | Kristalline Tigecyclin-Formen |
| US8198470B2 (en) * | 2006-04-24 | 2012-06-12 | Teva Pharmaceutical Industries Ltd. | Crystalline form II of tigecycline and processes for preparation thereof |
| WO2008066935A2 (en) * | 2006-11-29 | 2008-06-05 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of tigecycline and processes for preparation thereof |
| WO2008066908A1 (en) * | 2006-11-30 | 2008-06-05 | Teva Pharmaceutical Industries Ltd. | Processes for preparation of 9-haloacetamidominocyclines |
| EP2114865A1 (en) * | 2007-03-01 | 2009-11-11 | Teva Pharmaceutical Industries Ltd. | Processes for purification of tigecycline |
| US20090099376A1 (en) * | 2007-10-16 | 2009-04-16 | Wyeth | Tigecycline and methods of preparing intermediates |
| US9107929B2 (en) | 2008-05-01 | 2015-08-18 | Ranbaxy Laboratories Limited | Stable parenteral formulations of tigecycline |
| ITMI20080807A1 (it) | 2008-05-05 | 2009-11-06 | Antibioticos Spa | Procedimento per la preparazione di tigeciclina in forma amorfa |
| US20100035845A1 (en) * | 2008-08-06 | 2010-02-11 | Wyeth | Tigecycline formulations |
| JP2012520305A (ja) | 2009-03-12 | 2012-09-06 | ワイス・エルエルシー | テトラサイクリンのニトロ化 |
| CN103417498B (zh) * | 2012-05-18 | 2017-09-12 | 山东新时代药业有限公司 | 一种替加环素冻干粉针剂的制备方法 |
| IN2013MU01127A (enExample) | 2013-03-26 | 2015-05-01 | Astron Res Ltd | |
| WO2014167575A2 (en) | 2013-03-26 | 2014-10-16 | Astron Research Limited | Stable tigecycline composition |
| CN103202814A (zh) * | 2013-04-23 | 2013-07-17 | 成都百裕科技制药有限公司 | 一种注射用替加环素的制备方法 |
| CN105924367B (zh) * | 2016-04-18 | 2017-12-29 | 镇江高海生物药业有限公司 | 多西环素一水物的有关物质及其分析检测方法 |
| WO2019147755A1 (en) * | 2018-01-26 | 2019-08-01 | AL Pharma, Inc. | Manufacturing and packaging of a sterile drug product |
| CN108653216B (zh) * | 2018-05-28 | 2020-12-18 | 福安药业集团湖北人民制药有限公司 | 注射用替加环素 |
| WO2021063468A1 (en) | 2019-10-02 | 2021-04-08 | Anfarm Hellas S.A. | Stable parenteral pharmaceutical composition containing tigecycline and process for the preparation thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3026248A (en) * | 1959-09-11 | 1962-03-20 | Pfizer & Co C | Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents |
| US5494903A (en) * | 1991-10-04 | 1996-02-27 | American Cyanamid Company | 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines |
| US5284963A (en) * | 1992-08-13 | 1994-02-08 | American Cyanamid Company | Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines |
| US6660267B1 (en) * | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| US5675030A (en) * | 1994-11-16 | 1997-10-07 | American Cyanamid Company | Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound |
| EP1531828A4 (en) * | 2002-05-23 | 2005-11-02 | Activbiotics Inc | METHODS OF TREATING BACTERIAL INFECTIONS AND ASSOCIATED DISEASES |
| ATE415973T1 (de) * | 2004-10-28 | 2008-12-15 | Wyeth Corp | Gemeinsame gabe von tigecyclin und digoxin |
| KR20130122988A (ko) * | 2005-03-14 | 2013-11-11 | 와이어쓰 엘엘씨 | 티게사이클린 조성물 및 이의 제조방법 |
| AR057034A1 (es) | 2005-05-27 | 2007-11-14 | Wyeth Corp | Metodos para purificar tigeciclina |
-
2006
- 2006-06-15 PE PE2006000670A patent/PE20070072A1/es not_active Application Discontinuation
- 2006-06-15 AR ARP060102533A patent/AR055336A1/es unknown
- 2006-06-16 KR KR1020087001124A patent/KR20080024201A/ko not_active Withdrawn
- 2006-06-16 WO PCT/US2006/023613 patent/WO2006138641A2/en not_active Ceased
- 2006-06-16 JP JP2008517178A patent/JP2008543871A/ja active Pending
- 2006-06-16 SV SV2006002575A patent/SV2007002575A/es unknown
- 2006-06-16 BR BRPI0612228-0A patent/BRPI0612228A2/pt not_active IP Right Cessation
- 2006-06-16 AU AU2006261636A patent/AU2006261636A1/en not_active Abandoned
- 2006-06-16 CN CNA2006800213849A patent/CN101198315A/zh active Pending
- 2006-06-16 PA PA20068680201A patent/PA8680201A1/es unknown
- 2006-06-16 EP EP06773424A patent/EP1898884A2/en not_active Withdrawn
- 2006-06-16 RU RU2007145595/15A patent/RU2007145595A/ru not_active Application Discontinuation
- 2006-06-16 MX MX2007015960A patent/MX2007015960A/es unknown
- 2006-06-16 CA CA002610909A patent/CA2610909A1/en not_active Abandoned
- 2006-06-16 US US11/455,144 patent/US7705168B2/en not_active Expired - Fee Related
- 2006-06-16 TW TW095121834A patent/TW200716203A/zh unknown
- 2006-06-16 GT GT200600259A patent/GT200600259A/es unknown
-
2007
- 2007-12-05 NO NO20076264A patent/NO20076264L/no not_active Application Discontinuation
- 2007-12-06 IL IL187979A patent/IL187979A0/en unknown
- 2007-12-12 EC EC2007008005A patent/ECSP078005A/es unknown
- 2007-12-14 CR CR9594A patent/CR9594A/es unknown
- 2007-12-14 ZA ZA200710906A patent/ZA200710906B/xx unknown
-
2009
- 2009-06-05 JP JP2009136753A patent/JP2009191083A/ja not_active Withdrawn
- 2009-11-05 JP JP2009254475A patent/JP2010024252A/ja not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012515753A (ja) * | 2009-01-23 | 2012-07-12 | ホビオネ インテル リミテッド | チゲサイクリンの単離方法 |
| JP2015166347A (ja) * | 2009-01-23 | 2015-09-24 | ホビオネ インテル リミテッド | チゲサイクリンの単離方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| SV2007002575A (es) | 2007-01-03 |
| ECSP078005A (es) | 2008-01-23 |
| CN101198315A (zh) | 2008-06-11 |
| NO20076264L (no) | 2008-03-10 |
| US7705168B2 (en) | 2010-04-27 |
| MX2007015960A (es) | 2008-03-06 |
| CR9594A (es) | 2008-03-07 |
| US20070026080A1 (en) | 2007-02-01 |
| WO2006138641A2 (en) | 2006-12-28 |
| EP1898884A2 (en) | 2008-03-19 |
| BRPI0612228A2 (pt) | 2011-03-29 |
| GT200600259A (es) | 2007-05-08 |
| PA8680201A1 (es) | 2007-01-17 |
| KR20080024201A (ko) | 2008-03-17 |
| IL187979A0 (en) | 2008-03-20 |
| ZA200710906B (en) | 2009-03-25 |
| AR055336A1 (es) | 2007-08-22 |
| AU2006261636A1 (en) | 2006-12-28 |
| PE20070072A1 (es) | 2007-02-25 |
| TW200716203A (en) | 2007-05-01 |
| RU2007145595A (ru) | 2009-07-27 |
| WO2006138641A3 (en) | 2007-05-18 |
| JP2009191083A (ja) | 2009-08-27 |
| JP2010024252A (ja) | 2010-02-04 |
| CA2610909A1 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009191083A (ja) | チゲサイクリンのための製造プロセス | |
| US10683335B2 (en) | Freeze-dried preparation containing high-purity PTH and method for producing same | |
| KR101703980B1 (ko) | 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법 | |
| EP3305283B1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| JP2009539989A (ja) | 注射用アルテスン酸の処方及び製造方法 | |
| HK1207825B (zh) | 高纯度含pth冷冻干燥制剂及其制造方法 | |
| HK1190304B (en) | Freeze-dried preparation containing high-purity pth and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090605 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20090605 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20090701 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090706 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091005 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091105 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091218 |